Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma

Radosavljević, Gordana; Ljujić, Biljana; Jovanović, Ivan; Srzentic, Z; Pavlović, Sladjana; Zdravković, Nemanja; Milovanović, Marija; Banković, Dragić; Knežević, Milan; Acimovic, LD; Arsenijević, Nebojša

doi:10.4149/neo_2010_02_135

Cited by 45 publications

(37 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accumulating evidence indicates that IL-17 expression is aberrant in several human tumors, such as ovarian cancer,9 cervical cancer,10 breast cancer,11 hepatocellular carcinoma,12 esophageal cancer,13 gastric cancer,14 and colorectal cancer 15. But the underlying mechanism of IL-17 in tumor initiation and progression is not yet completely clear.…”

Section: Introductionmentioning

confidence: 99%

IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis

Dai¹,

Zhou²,

Tan³

et al. 2014

OTT

View full text Add to dashboard Cite

Interleukin (IL)-17 has been shown to play an important role in the pathogenesis of inflammation and cancer. The IL-17A (-197G/A) and IL-17F (7488T/C) polymorphisms have been extensively investigated with cancer risk, but individually published results have been inconclusive. The aim of this study was to clarify the effects of the IL-17A (-197G/A) and IL-17F (7488T/C) polymorphisms on cancer risk in Asian populations. Relevant studies were identified by searching databases extensively. The association between the IL-17A (-197G/A) and IL-17F (7488T/C) polymorphisms and cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs). A total of 12 articles with adequate information satisfied our inclusion criteria; these included 12 studies, with 4,540 cases and 5,875 controls, of IL-17A (-197G/A) polymorphism and seven studies, with 1,960 cases and 3,226 controls, of IL-17F (7488T/C) polymorphism. In the overall analysis, the IL-17A (-197G/A) polymorphism was significantly associated with increased cancer risk (P<0.05), for all genetic models. However, there was no statistically significant association between IL-17F (7488T/C) and cancer risk (P>0.05), for any genetic models. Furthermore, stratification by cancer type revealed a significant correlation between the IL-17A (-197G/A) polymorphism and cancer risk for all cancer types. When stratified by source of controls, a significant correlation was observed between the IL-17A (-197G/A) polymorphism and cancer risk in the population-based control subgroup but not in hospital-based control subgroup. In conclusion, our meta-analysis provides evidence that the IL-17A (-197G/A) polymorphism might be associated with cancer risk, while no evidence suggested a significant association between IL-17F (7488T/C) polymorphism and cancer risk.

show abstract

Section: Introductionmentioning

confidence: 99%

IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis

Dai¹,

Zhou²,

Tan³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

“…A study by Radosavljevic et al indicates that IL-17 levels are higher in CRC patients compared to normal controls. 64 This study used the same patient cohort as the Ljujic study. The authors concluded that IL-17 may be a useful tool for CRC diagnosis.…”

mentioning

confidence: 99%

The diagnostic and prognostic role of cytokines in colon cancer

Long¹,

Raufman²

2011

GICTT

View full text Add to dashboard Cite

In the United States, colorectal cancer (CRC) is the third most common cancer diagnosis in both men and women. Many patients are diagnosed with advanced stage CRC which has a high rate of mortality compared to localized CRC. Developing novel diagnostic tools is important for early detection to decrease both morbidity and mortality. Currently, colonoscopy is the most common screening test, though its effectiveness in reducing mortality remains uncertain and it is costly, invasive and carries risk. Stool-based tests such as fecal occult blood test and fecal immunochemical test for hemoglobin are relatively inexpensive, cause no discomfort and have no risk but lack sufficient specificity or sensitivity. Stool DNA tests may be more sensitive, but are not cost-effective and have not been sufficiently evaluated in population-based studies. To improve diagnostic efficacy, it is necessary to develop tests that limit patient discomfort and are cost-effective while providing adequate sensitivity and specificity. Elucidating serum biomarker profiles for various stages of CRC would provide a platform from which to develop enzyme-linked immunosorbent and multiplex bead array assays for clinical use. Both inflammation-induced and sporadic CRC trigger immune responses that are mediated by cytokine production. Many inflammatory serum proteins have been analyzed for their ability to predict cancer. Patient cohort studies have detected differential expression of inflammatory serum biomarkers in healthy controls compared to persons with various stages of CRC. Moreover, proteomics and animal research have uncovered additional serum factors implicated in CRC. Analysis of known differentially-expressed biomarkers along with further study of potential biomarkers may lead to clinically useful serum biomarker profiles for CRC.

show abstract

“…Radosavljevic et al have shown that it might act as a valuable tumor marker in patients with CRC by measuring IL-17A levels in the serum samples from CRC patients. 46 In the investigation of IL-17A's effect along human adenoma-carcinoma sequence, we have found that the elevation of IL-17A starts from the adenoma stage, and is related to the severity of dysplasia. Although the expression level of IL-17A at the cancer is even higher, it is not related to the TNM parameters of CRC.…”

mentioning

confidence: 97%

“…44 It is unknown whether IL-17 can enhance the production of IL-8 from CRC cells, however, both IL-17 and IL-8 have been found to be increased in patients with CRC. 5,31,45,46 It is necessary to further investigate whether IL-17A can stimulate IL-8 released from CRC cells in patients with CRC.…”

mentioning

confidence: 99%

The Role of Interleukin-17A in Colorectal Tumorigenesis

Shi

Lin²,

Cui³

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

It has been well documented that interleukin (IL)-17A mainly produced by the newly identified T cell subtype Th17 cells is an important proinflammatory cytokine that plays a vital pathogenic role in the process of human inflammatory bowel diseases. Recently, new information concerning the biological activities of IL-17A relating to the development of colorectal cancer (CRC) has also been reported. The present mini-review focuses on recent observations concerning the role of IL-17A in the development of CRCs, and it discusses the clinical significance of IL-17A as a biomarker and potential therapeutic target.

show abstract

Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma

Cited by 45 publications

References 56 publications

IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis

IL-17A (-197G/A) and IL-17F (7488T/C) gene polymorphisms and cancer risk in Asian population: a meta-analysis

The diagnostic and prognostic role of cytokines in colon cancer

The Role of Interleukin-17A in Colorectal Tumorigenesis

Contact Info

Product

Resources

About